EMA Application withdrawn: Multaq (dronedarone) — Sanofi-Aventis

View source ↗

Summary

EMA withdrew the application for Multaq (dronedarone) for atrial fibrillation/flutter.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Atrial Flutter

Drugs mentioned

• Multaq (dronedarone)

Snippet

Status: Application withdrawn. Therapeutic area: Atrial Fibrillation;Atrial Flutter. MAH: Sanofi-Aventis. Decision date: 31/12/2009